InDex Pharmaceuticals Holding AB (INDEX) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Cantargia AB

Oncopeptides AB

Xbrane Biopharma AB

Medivir AB

InDex Pharmaceuticals Holding AB

Orexo AB

Cereno Scientific AB

Diamyd Medical AB

SynAct Pharma AB

Initiator Pharma A/S

Kancera AB

Why is InDex Pharmaceuticals Holding AB ?

With a fall in Net Sales of -115.38%, the company declared Very Negative results in Jun 25

INTEREST(HY) At SEK 82.4 MM has Grown at 5,602.42%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -25.13%, its profits have risen by 70.8%

Below par performance in long term as well as near term

Along with generating -25.13% returns in the last 1 year, the stock has also underperformed OMX Stockholm 30 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is InDex Pharmaceuticals Holding AB for you?

Low Risk, Low Return

Absolute

Risk Adjusted

Volatility

InDex Pharmaceuticals Holding AB

-100.0%

-1.58

21.85%

OMX Stockholm 30

17.06%

0.95

17.88%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

51.42%

EBIT Growth (5y)

-182.57%

EBIT to Interest (avg)

-66.30

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.20

Sales to Capital Employed (avg)

0.14

Tax Ratio

1.20%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

0.61%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.73

EV to EBIT

-57.39

EV to EBITDA

-58.71

EV to Capital Employed

0.68

EV to Sales

103.82

PEG Ratio

Dividend Yield

ROCE (Latest)

-1.18%

ROE (Latest)

-1.53%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

24What is working for the Company

OPERATING CASH FLOW(Y)

Highest at SEK -16.8 MM

NET SALES(HY)

Higher at SEK 22 MM

RAW MATERIAL COST(Y)

Fallen by -99.99% (YoY

CASH AND EQV(HY)

Highest at SEK 1,539.4 MM

OPERATING PROFIT(Q)

Highest at SEK 158.6 MM

PRE-TAX PROFIT(Q)

Highest at SEK 174.2 MM

NET PROFIT(Q)

Highest at SEK 173.5 MM

-8What is not working for the Company

INTEREST(HY)

At SEK 82.4 MM has Grown at 5,602.42%

Here's what is working for InDex Pharmaceuticals Holding AB

Pre-Tax Profit

At SEK 174.2 MM has Grown at 325.14%

over average net sales of the previous four periods of SEK -77.37 MM

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (SEK MM)

Net Profit

At SEK 173.5 MM has Grown at 327.24%

over average net sales of the previous four periods of SEK -76.35 MM

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (SEK MM)

Net Sales

At SEK 22 MM has Grown at 101.21%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very positive

Net Sales (SEK MM)

Operating Cash Flow

Highest at SEK -16.8 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (SEK MM)

Net Sales

Higher at SEK 22 MM

than preceding 12 month period ended Jun 2025

MOJO Watch

In the half year the company has already crossed sales of the previous twelve months

Net Sales (SEK MM)

Operating Profit

Highest at SEK 158.6 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (SEK MM)

Pre-Tax Profit

Highest at SEK 174.2 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (SEK MM)

Net Profit

Highest at SEK 173.5 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (SEK MM)

Cash and Eqv

Highest at SEK 1,539.4 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Raw Material Cost

Fallen by -99.99% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for InDex Pharmaceuticals Holding AB

Interest

At SEK 82.4 MM has Grown at 5,602.42%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (SEK MM)